temozolomide and Astrocytoma studies

Astrocytoma: Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)

Research Excerpts

Excerpt	Relevance	Reference
"In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase-wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]."	9.51	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. ( Aldape, K; Atmodimedjo, PN; Baumert, BG; Baurain, JF; Brandes, AA; Brouwer, RWW; Cheung, KJ; Chinot, OL; Clement, PM; de Heer, I; Dubbink, HJ; Erridge, SC; French, PJ; Gill, S; Golfinopoulos, V; Gorlia, T; Griffin, M; Hoogstrate, Y; Jenkins, RB; Kros, JM; Mason, WP; McBain, C; Nowak, AK; Rogers, L; Rudà, R; Sanson, M; Taal, W; Tesileanu, CMS; van den Bent, MJ; van IJcken, WFJ; van Linde, ME; Vogelbaum, MA; von Deimling, A; Weller, M; Wesseling, P; Wheeler, H; Wick, W, 2022)
"To investigate the toxicity profile and establish an optimal dosing schedule of zotiraciclib with temozolomide in patients with recurrent high-grade astrocytoma."	9.41	Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. ( Aboud, O; Ahmad, S; Antony, R; Armstrong, TS; Boris, L; Bryla, C; Burton, EM; Butler, MK; Calvo, KR; Cordova, C; Figg, WD; Fink, D; Gallin, JI; Garren, N; Gilbert, MR; Gonzales, J; Grajkowska, E; Kuhns, DB; Leeper, H; Lindsley, M; Lollo, N; Long Priel, DA; Mendoza, TR; Mentges, K; Pang, Y; Peer, CJ; Penas-Prado, M; Siegel, C; Sissung, TM; Su, YT; Theeler, BJ; Vera, E; Wu, J; Yu, G; Yuan, Y, 2021)
"The primary objective of this study was to compare the overall survival (OS) of patients with anaplastic astrocytoma (AA) treated with radiotherapy (RT) and either temozolomide (TMZ) or a nitrosourea (NU)."	9.24	Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. ( Aldape, KD; Bahary, JP; Barger, GR; Belanger, K; Bell, EH; Brachman, D; Brown, PD; Cairncross, JG; Chakravarti, A; Chang, S; Dolinskas, CA; Gilbert, MR; Hunter, G; Jaeckle, K; Mehta, M; Penas-Prado, M; Robins, HI; Schiff, D; Schultz, C; Shih, H; Werner-Wasik, M; Zhang, P, 2017)
"Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage."	9.22	The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016)
"To evaluate the efficacy and safety of temozolomide (TMZ) versus semustine (Me-CCNU) in the treatment of recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA)."	9.17	[Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma]. ( Sun, J; Yang, SY; Yang, XJ, 2013)
" We did a randomised trial to compare the efficacy and safety of dose-dense temozolomide alone versus radiotherapy alone in elderly patients with anaplastic astrocytoma or glioblastoma."	9.16	Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. ( Braun, C; Combs, SE; Felsberg, J; Ketter, R; Mayer-Steinacker, R; Meisner, C; Meixensberger, J; Nikkhah, G; Papsdorf, K; Platten, M; Reifenberger, G; Sabel, M; Simon, M; Steinbach, JP; Tabatabai, G; Vesper, J; Weller, M; Wick, W, 2012)
"The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA)."	9.14	Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. ( Berkey, B; Biggs, C; Blumenthal, DT; Brown, P; Giannini, C; Herman, J; Jenkins, R; Macdonald, D; Mehta, M; Peereboom, D; Schultz, C; Suh, JH; Vogelbaum, MA, 2009)
"We retrospectively investigated the correlation of IDH1 and IDH2 mutations with overall survival and response to temozolomide in a cohort of patients with dedifferentiated low-grade astrocytomas treated with temozolomide at the time of progression after radiotherapy."	9.14	IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. ( Boogerd, W; Bromberg, JE; Dinjens, WN; Dubbink, HJ; Gijtenbeek, JM; Groenendijk, FH; Kros, JM; Postma, TJ; Smitt, PA; Taal, W; van den Bent, MJ; van Heuvel, I; van Marion, R; Zonnenberg, BA; Zonnenberg, CB, 2009)
"The primary objective of this prospective phase 2 study of CPT-11 in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival (PFS)."	9.13	Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. ( Blumenthal, DT; Chamberlain, MC; Glantz, MJ; Wei-Tsao, DD, 2008)
"A prospective Phase II study of cyclophosphamide (CYC) was conducted in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) with a primary objective of evaluating 6-month progression-free survival (PFS)."	9.12	Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. ( Chamberlain, MC; Groshen, S; Tsao-Wei, DD, 2006)
"Temozolomide (TMZ) a recent, oral, second generation alkylating agent is a chemotherapeutic with demonstrated efficacy for the treatment of high-grade gliomas."	9.12	Surgery, radiotherapy and temozolomide in treating high-grade gliomas. ( Barbarisi, M; Moraci, A; Moraci, M; Parlato, C, 2006)
"Based on our findings in two paediatric patients, temozolomide may be a useful agent in the management of progressive recurrent low grade spinal cord astrocytomas."	9.12	Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients. ( Abboud, MR; Al Kutoubi, AO; Alaraj, AM; Chamoun, RB; Haddad, GF, 2006)
"The efficacy and safety of temozolomide were evaluated in 32 patients with anaplastic astrocytoma at first relapse."	9.12	[Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]. ( Aoki, T; Fujimaki, T; Hori, T; Ikeda, J; Kochi, M; Maruno, M; Matsutani, M; Nakamura, H; Nishikawa, R; Sato, S; Sawamura, Y; Shibui, S; Sugiyama, K; Takahashi, H; Takahashi, J; Wakabayashi, T, 2006)
"To determine the safety and toxicity of carmustine (BCNU) and temozolomide (TMZ) with radiotherapy (RT) in newly diagnosed anaplastic astrocytoma."	9.11	Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. ( Atkins, J; Bahary, JP; Barger, G; Buckner, J; Bushunow, P; Cairncross, G; Chang, SM; Choucair, A; Curran, W; Dolinskas, C; Gilbert, M; Kresl, J; Louis, DN; Mehta, M; Seiferheld, W; Share, R; Thoron, L, 2004)
"The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma."	9.11	Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. ( Allgeier, A; Brandes, AA; Enting, RH; Frenay, M; Kros, JM; Menten, J; Stege, EB; Taphoorn, MJ; Tosoni, A; Triebels, VH; van den Bent, MJ; van Heuvel, I, 2004)
"Seventy-five consecutive patients with recurrent malignant astrocytomas and glioblastomas had been treated at our institute with per os temozolomide for five days every month."	9.11	Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas. ( Afra, D; Sipos, L; Vitanovics, D, 2004)
"Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma."	9.10	Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003)
"To determine the antitumor efficacy and safety profile of temozolomide in patients with malignant astrocytoma at first relapse."	9.09	Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. ( Albright, R; Brada, M; Bruner, J; Chang, SM; Dugan, M; Friedman, AH; Friedman, HS; Levin, VA; O'Neill, AM; Olson, J; Prados, MD; Rosenfeld, SS; Yaya-Tur, R; Yue, N; Yung, WK; Zaknoen, S, 1999)
"One of the objectives of this phase II study was to determine whether temozolomide (TMZ) improved the health-related quality of life (HRQL) of patients with recurrent anaplastic astrocytoma (AA)."	9.09	Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. ( Brada, M; Osoba, D; Prados, MD; Yung, WK, 2000)
" A novel second-generation alkylating agent, temozolomide, has recently demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme and anaplastic astrocytoma."	9.09	Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. ( Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Grisoli, F; Honore, S; Martin, PM; Muracciole, X, 2001)
"To report the long-term outcomes in adult patients with grade 2 IDH-mutant astrocytoma treated with temozolomide (TMZ)-based chemoradiation."	8.31	Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma. ( Antonelli, M; Arcella, A; Bozzao, A; Capone, L; De Pietro, R; Esposito, V; Gianno, F; Giraffa, M; Lanzetta, G; Minniti, G; Paolini, S; Romano, A; Tini, P, 2023)
"The role of temozolomide chemotherapy alone in isocitrate dehydrogenase (IDH)-mutant astrocytomas has not been conclusively determined."	8.12	Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3. ( Becker, H; Blobner, J; Egensperger, R; Katzendobler, S; Niyazi, M; Quach, S; Suchorska, B; Thiele, F; Thon, N; Tonn, JC; Weller, J; Weller, M, 2022)
"IDH-mutant anaplastic astrocytomas (AAs) are chemosensitive tumors for which the best choice of adjuvant chemotherapy between procarbazine, lomustine, and vincristine (PCV) or temozolomide (TMZ) after radiotherapy (RT) remains unclear."	8.02	Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. ( Bronniman, C; Carpentier, C; Ciron, DL; Dehais, C; Ducray, F; Esteyrie, V; Figarella-Branger, D; Martin, E; Moyal, EC; Network, P; Pouessel, D; Uro-Coste, E, 2021)
"To report clinical outcomes of temozolomide (TMZ)-based radio-chemotherapy and adjuvant chemotherapy in patients with aggressive/high-risk low-grade glioma (LGG)."	8.02	Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy. ( Anand, S; Chatterjee, A; Epari, S; Goda, JS; Gupta, T; Jalali, R; Krishnatry, R; Moiyadi, A; Panda, P; Patil, V, 2021)
"This is the long-term update of NOA-08 (NCT01502241), which compared efficacy and safety of radiotherapy (RT, n = 176) and temozolomide (TMZ, n = 193) at 7/14 days in patients >65 years old with anaplastic astrocytoma or glioblastoma."	7.96	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. ( Bamberg, M; Bölting, H; Debus, J; Felsberg, J; Herrlinger, U; Hertler, C; Kessler, T; Ketter, R; Mayer-Steinacker, R; Meisner, C; Meixensberger, J; Papsdorf, K; Platten, M; Reifenberger, G; Reuss, D; Sabel, M; Sahm, F; Steinbach, JP; Vesper, J; von Deimling, A; Weisang, S; Weller, M; Weyerbrock, A; Wick, A; Wick, W, 2020)
"A standard post-concomitant radiochemotherapy involving adjuvant temozolomide (TMZ) was stopped after 6 cycles for high-grade gliomas (HGG)."	7.88	Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV). ( Ho, JT; Ho, RW; Lin, WC; Lin, YJ; Lin, YT; Lu, CH; Tsai, NW; Wang, HC, 2018)
"Postoperative management of anaplastic glioma remains without a clear standard of care-in this study we report outcomes for patients treated with radiotherapy (RT) with and without temozolomide (TMZ)."	7.88	Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. ( Chan, MD; Debinski, W; Farris, M; Helis, C; Laxton, AW; Lesser, GJ; Lo, HW; Lucas, JT; McTyre, E; Mott, R; Soike, M; Strowd, RE; Tatter, SB, 2018)
"Temozolomide (TMZ) for malignant gliomas is traditionally dosed in 5 out of a 28-day cycle, however alternative regimens exist, including dose-dense."	7.85	Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma. ( Howard, TA; Villano, JL; Zhou, Z, 2017)
"We retrospectively analyzed the data of 5 adult patients treated with temozolomide between 2008 and 2015 for a grade II intramedullary astrocytoma with progression after surgery."	7.85	[Contribution of temozolomide chemotherapy for intramedullary grade II spinal cord astrocytomas in adults: Our experience]. ( Chaskis, E; De Witte, O; Devriendt, D; Goldman, S; Lefranc, F; Luce, S; Minichini, V; Sadeghi, N, 2017)
"To explore the efficacy and toxicity of an extended schedule of temozolomide (50 mg/mq 1 week on/1 week off) in a population of newly diagnosed low-grade gliomas (LGG)."	7.85	Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up. ( Carapella, CM; Carosi, M; Fabi, A; Giannarelli, D; Marucci, L; Maschio, M; Merola, R; Pace, A; Vidiri, A; Villani, V, 2017)
"It is currently unclear whether adjuvant therapy for WHO grade III anaplastic astrocytomas (AA) should be carried out as combined chemoradiotherapy with temozolomide (TMZ)--analogous to the approach for glioblastoma multiforme--or as radiotherapy (RT) alone."	7.81	Adjuvant temozolomide-based chemoradiotherapy versus radiotherapy alone in patients with WHO III astrocytoma: The Mainz experience. ( Giese, A; Mayer, A; Renovanz, M; Schmidberger, H; Schwanbeck, C; Sommer, C; Stockinger, M; Vaupel, P, 2015)
" We report a retrospective multicenter study of 97 consecutive adult patients with anaplastic astrocytoma (AA) treated with radiation therapy (RT) plus concomitant and adjuvant temozolomide (TMZ) between October 2004 and March 2012."	7.80	IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. ( Arcella, A; Bozzao, A; Di Stefano, D; Enrici, RM; Esposito, V; Giangaspero, F; Lanzetta, G; Minniti, G; Pace, A; Salvati, M; Scaringi, C; Scarpino, S; Villani, V, 2014)
"This study assesses the controversial role of temozolomide (TMZ) concurrent with adjuvant radiation (RT) in patients with anaplastic astrocytoma (AA)."	7.80	The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. ( Buckner, JC; Decker, PA; Giannini, C; Hardie, J; Jenkins, RB; Kizilbash, SH; Laack, NN; Parney, IF; Uhm, JH; Voss, JS, 2014)
" honey (ESH), beebread (EBB), and royal jelly (ERJ) with and without temozolomide (TMZ) on cell lines derived from a patient with diffuse astrocytoma (DASC), human glioblastoma multiforme (U87MG), and normal human astroglia (SVGp12)."	7.80	The interaction of bee products with temozolomide in human diffuse astrocytoma, glioblastoma multiforme and astroglia cell lines. ( Bartosiuk, E; Borawska, MH; Kochanowicz, J; Mariak, Z; Markiewicz-Żukowska, R; Moskwa, J; Naliwajko, SK; Socha, K; Surażyński, A, 2014)
"Only a few studies examined the effect of temozolomide (TMZ) in recurrent low-grade astrocytoma (LGA) after surgery, none of which included a homogeneous and sufficiently sized group of patients with progression after radiotherapy (RT)."	7.77	First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. ( Boogerd, W; Bromberg, JE; Dinjens, WN; Dubbink, HJ; Gijtenbeek, JM; Groenendijk, FH; Kouwenhoven, MC; Kros, JM; Postma, TJ; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Holt, B; van Heuvel, I; van Marion, R; Zonnenberg, BA; Zonnenberg, CB, 2011)
"The aim of the present study was to investigate the kinetics of the effects exerted by Temodal and quercetin on the survival of the human astrocytoma MOGGCCM cell line."	7.77	Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells. ( Jakubowicz-Gil, J; Langner, E; Rzeski, W, 2011)
"The aim of the present study was to investigate the effect of Temozolomide (an alkylating chemotherapeutic agent) and quercetin (natural flavonoid) on cell death in the human astrocytoma cell line MOGGCCM (WHO grade III)."	7.76	Temozolomide, quercetin and cell death in the MOGGCCM astrocytoma cell line. ( Jakubowicz-Gil, J; Langner, E; Piersiak, T; Rzeski, W; Wertel, I, 2010)
"We present a case of a 12-year-old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ)."	7.76	Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. ( Hosono, A; Makimoto, A; Miyakita, Y; Momota, H; Nariata, Y; Narita, Y; Shibui, S, 2010)
"Temozolomide is an oral alkylating agent approved for the treatment of glioblastoma and anaplastic astrocytoma, and is currently under clinical investigation for the treatment of brain metastases from a variety of cancers."	7.76	Urticarial hypersensitivity reaction caused by temozolomide. ( Hsu, MY; Ibrahimi, OA; Kesari, S; Pothiawala, S; Yang, C, 2010)
"Temozolomide (TMZ) is an alkylating agent used in the management of gliomas."	7.75	Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? ( Bell, D; Khasraw, M; Wheeler, H, 2009)
" In this study, the authors investigate the nature of the SP phenotype in 2 glioma cell lines, U87MG and T98G, and their response to temozolomide."	7.74	Characterization of a side population of astrocytoma cells in response to temozolomide. ( Ang, BT; Chong, KH; Chua, C; See, SJ; Tang, C; Wong, MC; Zaiden, N, 2008)
"Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival."	7.74	Fatal outcome related to carmustine implants in glioblastoma multiforme. ( Barcia, JA; Barcia-Mariño, C; Gallego, JM, 2007)
"We compared survival in patients with anaplastic astrocytoma (AA) treated with adjuvant procarbazine, lomustine, and vincristine (PCV) with survival in patients treated with temozolomide."	7.73	Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. ( Brandes, AA; Ermani, M; Gardiman, M; Ghimenton, C; Iuzzolino, P; Nicolardi, L; Reni, M; Rotilio, A; Sotti, G; Tosoni, A, 2006)
"To assess whether the survival of patients with recurrent malignant glioma receiving temozolomide in everyday practice is comparable to that reported in previous studies."	7.72	Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. ( Maltoni, S; Messori, A; Pelagotti, F; Trippoli, S; Vacca, F; Vaiani, M, 2003)
"Patients with newly diagnosed anaplastic astrocytoma (AA) or anaplastic oligo-astrocytoma (AOA) were treated with concurrent radiotherapy (60 Gy over 6 weeks) and temozolomide (75 mg/m(2)), and six adjuvant 28-day cycles of either dose-dense (150 mg/m(2), days 1-7, 15-21) or metronomic (50 mg/m(2), days 1-28) temozolomide."	6.80	Radiotherapy and temozolomide for anaplastic astrocytic gliomas. ( Abrey, LE; Braunthal, SG; DeAngelis, LM; Huse, JT; Lassman, AB; Nayak, L; Panageas, KS; Pentsova, E; Reiner, AS, 2015)
"We conducted a study to determine the dose-limiting toxicity of an extended dosing schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), taking advantage of TMZ's ability to deplete O6-alkylguanine-DNA-alkyltransferase and the synergistic activity of these two agents."	6.71	Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. ( Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004)
"Temozolomide is a novel, oral, second-generation alkylating agent."	6.41	Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. ( Friedman, HS, 2000)
"Temozolomide, a new drug, has shown promise in treating malignant gliomas and other difficult-to-treat tumors."	6.41	Temozolomide and treatment of malignant glioma. ( Calvert, H; Friedman, HS; Kerby, T, 2000)
" For patients with recurrent malignant glioma, temozolomide provides a therapeutic option with a predictable safety profile, clinical efficacy, and convenient dosing that can provide important quality-of-life benefits."	6.41	Temozolomide for recurrent high-grade glioma. ( Macdonald, DR, 2001)
"In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase-wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]."	5.51	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. ( Aldape, K; Atmodimedjo, PN; Baumert, BG; Baurain, JF; Brandes, AA; Brouwer, RWW; Cheung, KJ; Chinot, OL; Clement, PM; de Heer, I; Dubbink, HJ; Erridge, SC; French, PJ; Gill, S; Golfinopoulos, V; Gorlia, T; Griffin, M; Hoogstrate, Y; Jenkins, RB; Kros, JM; Mason, WP; McBain, C; Nowak, AK; Rogers, L; Rudà, R; Sanson, M; Taal, W; Tesileanu, CMS; van den Bent, MJ; van IJcken, WFJ; van Linde, ME; Vogelbaum, MA; von Deimling, A; Weller, M; Wesseling, P; Wheeler, H; Wick, W, 2022)
"A 43-year-old man with an anaplastic astrocytoma received radiation therapy synchronized with ranimustine and adjuvant TMZ chemotherapy for 15 cycles."	5.46	A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma. ( Kosugi, K; Saito, K; Takahashi, W; Tokuda, Y; Tomita, H, 2017)
"Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14."	5.43	Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. ( Ajit, NE; Burton, GV; El-Osta, H; Peddi, P, 2016)
"To investigate the toxicity profile and establish an optimal dosing schedule of zotiraciclib with temozolomide in patients with recurrent high-grade astrocytoma."	5.41	Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. ( Aboud, O; Ahmad, S; Antony, R; Armstrong, TS; Boris, L; Bryla, C; Burton, EM; Butler, MK; Calvo, KR; Cordova, C; Figg, WD; Fink, D; Gallin, JI; Garren, N; Gilbert, MR; Gonzales, J; Grajkowska, E; Kuhns, DB; Leeper, H; Lindsley, M; Lollo, N; Long Priel, DA; Mendoza, TR; Mentges, K; Pang, Y; Peer, CJ; Penas-Prado, M; Siegel, C; Sissung, TM; Su, YT; Theeler, BJ; Vera, E; Wu, J; Yu, G; Yuan, Y, 2021)
"The treatment of anaplastic astrocytoma (AA) is controversial."	5.40	Chemotherapeutic resistance in anaplastic astrocytoma cell lines treated with a temozolomide-lomeguatrib combination. ( Canpinar, H; Castresana, JS; Ilgaz, S; Rey, JA; Sert, F; Sunguroglu, A; Taspinar, M; Ugur, HC, 2014)
"Temozolomide was used almost exclusively during CRT (94."	5.39	Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. ( Cahill, D; Gilbert, MR; Lei, X; Shonka, NA; Smith, L; Theeler, B; Yung, A, 2013)
"Temozolomide (TMZ) is an alkylating agent primarily used to treat tumors of the central nervous system."	5.39	Central diabetes insipidus: a previously unreported side effect of temozolomide. ( Faje, AT; Klibanski, A; Makimura, H; Miller, KK; Nachtigall, L; Wexler, D, 2013)
"The tumor was partially resected and anaplastic astrocytoma was diagnosed."	5.38	Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis. ( Fujimoto, Y; Hashimoto, N; Kagawa, N; Kinoshita, M; Miyazaki, Y; Takehara, T; Tanaka, S; Yakushijin, T; Yoshimine, T, 2012)
"The primary objective of this study was to compare the overall survival (OS) of patients with anaplastic astrocytoma (AA) treated with radiotherapy (RT) and either temozolomide (TMZ) or a nitrosourea (NU)."	5.24	Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. ( Aldape, KD; Bahary, JP; Barger, GR; Belanger, K; Bell, EH; Brachman, D; Brown, PD; Cairncross, JG; Chakravarti, A; Chang, S; Dolinskas, CA; Gilbert, MR; Hunter, G; Jaeckle, K; Mehta, M; Penas-Prado, M; Robins, HI; Schiff, D; Schultz, C; Shih, H; Werner-Wasik, M; Zhang, P, 2017)
"Cabozantinib inhibits mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2) and has demonstrated activity in patients with recurrent glioblastoma, warranting evaluation of the addition of cabozantinib to radiotherapy (RT) and temozolomide (TMZ) for patients with newly diagnosed high-grade glioma."	5.22	Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. ( Chamberlain, MC; Cloughesy, T; Desjardins, A; Glantz, M; Mikkelsen, T; Reardon, DA; Schiff, D; Wen, PY, 2016)
"Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage."	5.22	The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016)
"To evaluate the efficacy and safety of temozolomide (TMZ) versus semustine (Me-CCNU) in the treatment of recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA)."	5.17	[Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma]. ( Sun, J; Yang, SY; Yang, XJ, 2013)
" We did a randomised trial to compare the efficacy and safety of dose-dense temozolomide alone versus radiotherapy alone in elderly patients with anaplastic astrocytoma or glioblastoma."	5.16	Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. ( Braun, C; Combs, SE; Felsberg, J; Ketter, R; Mayer-Steinacker, R; Meisner, C; Meixensberger, J; Nikkhah, G; Papsdorf, K; Platten, M; Reifenberger, G; Sabel, M; Simon, M; Steinbach, JP; Tabatabai, G; Vesper, J; Weller, M; Wick, W, 2012)
"The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA)."	5.14	Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. ( Berkey, B; Biggs, C; Blumenthal, DT; Brown, P; Giannini, C; Herman, J; Jenkins, R; Macdonald, D; Mehta, M; Peereboom, D; Schultz, C; Suh, JH; Vogelbaum, MA, 2009)
"We retrospectively investigated the correlation of IDH1 and IDH2 mutations with overall survival and response to temozolomide in a cohort of patients with dedifferentiated low-grade astrocytomas treated with temozolomide at the time of progression after radiotherapy."	5.14	IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. ( Boogerd, W; Bromberg, JE; Dinjens, WN; Dubbink, HJ; Gijtenbeek, JM; Groenendijk, FH; Kros, JM; Postma, TJ; Smitt, PA; Taal, W; van den Bent, MJ; van Heuvel, I; van Marion, R; Zonnenberg, BA; Zonnenberg, CB, 2009)
"Temozolomide (TMZ) is an oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma multiforme (GBM)."	5.14	The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study. ( Abo Hamar, AH; El-Shorbagy, D; Galal, S; Shawky, H; Zakaria, F, 2009)
"The primary objective of this prospective phase 2 study of CPT-11 in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival (PFS)."	5.13	Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. ( Blumenthal, DT; Chamberlain, MC; Glantz, MJ; Wei-Tsao, DD, 2008)
"A prospective Phase II study of cyclophosphamide (CYC) was conducted in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) with a primary objective of evaluating 6-month progression-free survival (PFS)."	5.12	Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. ( Chamberlain, MC; Groshen, S; Tsao-Wei, DD, 2006)
"Temozolomide (TMZ) a recent, oral, second generation alkylating agent is a chemotherapeutic with demonstrated efficacy for the treatment of high-grade gliomas."	5.12	Surgery, radiotherapy and temozolomide in treating high-grade gliomas. ( Barbarisi, M; Moraci, A; Moraci, M; Parlato, C, 2006)
"Based on our findings in two paediatric patients, temozolomide may be a useful agent in the management of progressive recurrent low grade spinal cord astrocytomas."	5.12	Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients. ( Abboud, MR; Al Kutoubi, AO; Alaraj, AM; Chamoun, RB; Haddad, GF, 2006)
"The efficacy and safety of temozolomide were evaluated in 32 patients with anaplastic astrocytoma at first relapse."	5.12	[Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]. ( Aoki, T; Fujimaki, T; Hori, T; Ikeda, J; Kochi, M; Maruno, M; Matsutani, M; Nakamura, H; Nishikawa, R; Sato, S; Sawamura, Y; Shibui, S; Sugiyama, K; Takahashi, H; Takahashi, J; Wakabayashi, T, 2006)
"Although overall objective responses were limited, further exploration of temozolomide may be warranted in children with medulloblastoma and other PNETs, or in patients with low-grade astrocytoma, perhaps in a setting of less pretreatment than the patients in the current study, or in the context of multiagent therapy."	5.12	Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. ( Bernstein, M; Fort, D; Friedman, H; Harris, MB; Kadota, R; Krailo, M; Kretschmar, CS; Mazewski, C; Nicholson, HS; Reaman, GH; Sato, J; Tedeschi-Blok, N, 2007)
"To determine the safety and toxicity of carmustine (BCNU) and temozolomide (TMZ) with radiotherapy (RT) in newly diagnosed anaplastic astrocytoma."	5.11	Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. ( Atkins, J; Bahary, JP; Barger, G; Buckner, J; Bushunow, P; Cairncross, G; Chang, SM; Choucair, A; Curran, W; Dolinskas, C; Gilbert, M; Kresl, J; Louis, DN; Mehta, M; Seiferheld, W; Share, R; Thoron, L, 2004)
"The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma."	5.11	Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. ( Allgeier, A; Brandes, AA; Enting, RH; Frenay, M; Kros, JM; Menten, J; Stege, EB; Taphoorn, MJ; Tosoni, A; Triebels, VH; van den Bent, MJ; van Heuvel, I, 2004)
"Seventy-five consecutive patients with recurrent malignant astrocytomas and glioblastomas had been treated at our institute with per os temozolomide for five days every month."	5.11	Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas. ( Afra, D; Sipos, L; Vitanovics, D, 2004)
"Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma."	5.10	Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003)
"To determine the antitumor efficacy and safety profile of temozolomide in patients with malignant astrocytoma at first relapse."	5.09	Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. ( Albright, R; Brada, M; Bruner, J; Chang, SM; Dugan, M; Friedman, AH; Friedman, HS; Levin, VA; O'Neill, AM; Olson, J; Prados, MD; Rosenfeld, SS; Yaya-Tur, R; Yue, N; Yung, WK; Zaknoen, S, 1999)
"One of the objectives of this phase II study was to determine whether temozolomide (TMZ) improved the health-related quality of life (HRQL) of patients with recurrent anaplastic astrocytoma (AA)."	5.09	Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. ( Brada, M; Osoba, D; Prados, MD; Yung, WK, 2000)
" A novel second-generation alkylating agent, temozolomide, has recently demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme and anaplastic astrocytoma."	5.09	Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. ( Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Grisoli, F; Honore, S; Martin, PM; Muracciole, X, 2001)
" Temozolomide, a monofunctional alkylator, was the first chemotherapeutic agent to definitively improve survival in adults with newly diagnosed glioblastoma used in combination with radiation therapy with the most pronounced effect being in a subgroup of tumors with MGMT promoter methylation."	4.98	Chemotherapy of High-Grade Astrocytomas in Adults. ( Hoang, N; Puduvalli, VK, 2018)
" Temozolomide is a novel second-generation alkylating agent that has shown efficacy for the treatment of high-grade gliomas."	4.84	[Glioma therapy up-date]. ( Dalmau, J; de la Fuente, BP; Rosenfeld, M, 2007)
" We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ)."	4.82	Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. ( Chang, MC; Chiang, MF; Hsieh, RK; Su, YW, 2005)
"To report the long-term outcomes in adult patients with grade 2 IDH-mutant astrocytoma treated with temozolomide (TMZ)-based chemoradiation."	4.31	Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma. ( Antonelli, M; Arcella, A; Bozzao, A; Capone, L; De Pietro, R; Esposito, V; Gianno, F; Giraffa, M; Lanzetta, G; Minniti, G; Paolini, S; Romano, A; Tini, P, 2023)
"The role of temozolomide chemotherapy alone in isocitrate dehydrogenase (IDH)-mutant astrocytomas has not been conclusively determined."	4.12	Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3. ( Becker, H; Blobner, J; Egensperger, R; Katzendobler, S; Niyazi, M; Quach, S; Suchorska, B; Thiele, F; Thon, N; Tonn, JC; Weller, J; Weller, M, 2022)
"IDH-mutant anaplastic astrocytomas (AAs) are chemosensitive tumors for which the best choice of adjuvant chemotherapy between procarbazine, lomustine, and vincristine (PCV) or temozolomide (TMZ) after radiotherapy (RT) remains unclear."	4.02	Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. ( Bronniman, C; Carpentier, C; Ciron, DL; Dehais, C; Ducray, F; Esteyrie, V; Figarella-Branger, D; Martin, E; Moyal, EC; Network, P; Pouessel, D; Uro-Coste, E, 2021)
"To report clinical outcomes of temozolomide (TMZ)-based radio-chemotherapy and adjuvant chemotherapy in patients with aggressive/high-risk low-grade glioma (LGG)."	4.02	Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy. ( Anand, S; Chatterjee, A; Epari, S; Goda, JS; Gupta, T; Jalali, R; Krishnatry, R; Moiyadi, A; Panda, P; Patil, V, 2021)
"This is the long-term update of NOA-08 (NCT01502241), which compared efficacy and safety of radiotherapy (RT, n = 176) and temozolomide (TMZ, n = 193) at 7/14 days in patients >65 years old with anaplastic astrocytoma or glioblastoma."	3.96	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. ( Bamberg, M; Bölting, H; Debus, J; Felsberg, J; Herrlinger, U; Hertler, C; Kessler, T; Ketter, R; Mayer-Steinacker, R; Meisner, C; Meixensberger, J; Papsdorf, K; Platten, M; Reifenberger, G; Reuss, D; Sabel, M; Sahm, F; Steinbach, JP; Vesper, J; von Deimling, A; Weisang, S; Weller, M; Weyerbrock, A; Wick, A; Wick, W, 2020)
" Here, diffusion MRI data were acquired in a GL261 glioma mouse model before and during treatment with Temozolomide."	3.96	Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response. ( Agliardi, G; Alexander, DC; Atkinson, D; Brandner, S; Breen-Norris, JO; d'Esposito, A; Hipwell, B; Hyare, H; Ianus, A; Lythgoe, MF; Panagiotaki, E; Punwani, S; Ramasawmy, R; Rees, J; Roberts, TA; Siow, B; Taylor, V; Walker-Samuel, S, 2020)
"Oxygen 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a significant prognostic biomarker in astrocytomas, especially for temozolomide (TMZ) chemotherapy."	3.91	A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication. ( Dong, D; Gu, D; Hao, X; Tan, Y; Tian, J; Wang, L; Wang, X; Wei, J; Yang, G; Zhang, H; Zhang, S, 2019)
" However, a randomized controlled study (RTOG 9802) showed that adding of procarbazine, CCNU, and vincristine (PCV) chemotherapy to fractionated radiotherapy (FRT) in patients with "high-risk" WHO grade II gliomas, including DA, has significant positive impact on both progression-free survival and overall survival."	3.88	Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults. ( Narita, Y, 2018)
"A standard post-concomitant radiochemotherapy involving adjuvant temozolomide (TMZ) was stopped after 6 cycles for high-grade gliomas (HGG)."	3.88	Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV). ( Ho, JT; Ho, RW; Lin, WC; Lin, YJ; Lin, YT; Lu, CH; Tsai, NW; Wang, HC, 2018)
"Postoperative management of anaplastic glioma remains without a clear standard of care-in this study we report outcomes for patients treated with radiotherapy (RT) with and without temozolomide (TMZ)."	3.88	Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. ( Chan, MD; Debinski, W; Farris, M; Helis, C; Laxton, AW; Lesser, GJ; Lo, HW; Lucas, JT; McTyre, E; Mott, R; Soike, M; Strowd, RE; Tatter, SB, 2018)
"MOGGCCM (anaplastic astrocytoma) and T98G (glioblastoma multiforme) cell lines incubated with sorafenib and/or Temozolomide were used in the experiments."	3.85	Temozolomide and sorafenib as programmed cell death inducers of human glioma cells. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I; Zając, A, 2017)
"Temozolomide (TMZ) for malignant gliomas is traditionally dosed in 5 out of a 28-day cycle, however alternative regimens exist, including dose-dense."	3.85	Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma. ( Howard, TA; Villano, JL; Zhou, Z, 2017)
"We retrospectively analyzed the data of 5 adult patients treated with temozolomide between 2008 and 2015 for a grade II intramedullary astrocytoma with progression after surgery."	3.85	[Contribution of temozolomide chemotherapy for intramedullary grade II spinal cord astrocytomas in adults: Our experience]. ( Chaskis, E; De Witte, O; Devriendt, D; Goldman, S; Lefranc, F; Luce, S; Minichini, V; Sadeghi, N, 2017)
"To explore the efficacy and toxicity of an extended schedule of temozolomide (50 mg/mq 1 week on/1 week off) in a population of newly diagnosed low-grade gliomas (LGG)."	3.85	Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up. ( Carapella, CM; Carosi, M; Fabi, A; Giannarelli, D; Marucci, L; Maschio, M; Merola, R; Pace, A; Vidiri, A; Villani, V, 2017)
"It is currently unclear whether adjuvant therapy for WHO grade III anaplastic astrocytomas (AA) should be carried out as combined chemoradiotherapy with temozolomide (TMZ)--analogous to the approach for glioblastoma multiforme--or as radiotherapy (RT) alone."	3.81	Adjuvant temozolomide-based chemoradiotherapy versus radiotherapy alone in patients with WHO III astrocytoma: The Mainz experience. ( Giese, A; Mayer, A; Renovanz, M; Schmidberger, H; Schwanbeck, C; Sommer, C; Stockinger, M; Vaupel, P, 2015)
" We report a retrospective multicenter study of 97 consecutive adult patients with anaplastic astrocytoma (AA) treated with radiation therapy (RT) plus concomitant and adjuvant temozolomide (TMZ) between October 2004 and March 2012."	3.80	IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. ( Arcella, A; Bozzao, A; Di Stefano, D; Enrici, RM; Esposito, V; Giangaspero, F; Lanzetta, G; Minniti, G; Pace, A; Salvati, M; Scaringi, C; Scarpino, S; Villani, V, 2014)
"This study assesses the controversial role of temozolomide (TMZ) concurrent with adjuvant radiation (RT) in patients with anaplastic astrocytoma (AA)."	3.80	The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. ( Buckner, JC; Decker, PA; Giannini, C; Hardie, J; Jenkins, RB; Kizilbash, SH; Laack, NN; Parney, IF; Uhm, JH; Voss, JS, 2014)
" honey (ESH), beebread (EBB), and royal jelly (ERJ) with and without temozolomide (TMZ) on cell lines derived from a patient with diffuse astrocytoma (DASC), human glioblastoma multiforme (U87MG), and normal human astroglia (SVGp12)."	3.80	The interaction of bee products with temozolomide in human diffuse astrocytoma, glioblastoma multiforme and astroglia cell lines. ( Bartosiuk, E; Borawska, MH; Kochanowicz, J; Mariak, Z; Markiewicz-Żukowska, R; Moskwa, J; Naliwajko, SK; Socha, K; Surażyński, A, 2014)
"The aim of the present study was to investigate whether silencing of Hsp27 or Hsp72 expression in glioblastoma multiforme T98G and anaplastic astrocytoma MOGGCCM cells increases their sensitivity to programmed cell death induction upon temozolomide and/or quercetin treatment."	3.79	Silencing of Hsp27 and Hsp72 in glioma cells as a tool for programmed cell death induction upon temozolomide and quercetin treatment. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2013)
"Few studies have assessed the presentation, management, and outcome of anaplastic astrocytoma (AA) in elderly patients in the temozolomide era."	3.78	Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma. ( Buckner, JC; Meyer, FB; Parney, IF; Tanaka, S; Uhm, JH; Yan, ES, 2012)
"To test the effect of starvation on glioma cells in vitro, we treated primary mouse glia, murine GL26, rat C6 and human U251, LN229 and A172 glioma cells with Temozolomide in ad lib and STS mimicking conditions."	3.78	Fasting enhances the response of glioma to chemo- and radiotherapy. ( Brandhorst, S; Chen, TC; Conti, PS; Hwang, S; Lee, C; Longo, VD; Safdie, F; Wang, W; Wei, M, 2012)
" Here, we report on celecoxib desensitization after a celecoxib-induced skin reaction, thereby allowing the continuation of temozolomide/celecoxib chemotherapy in a young patient with recurrent astrocytoma."	3.78	Celecoxib desensitization: continued temozolomide/celecoxib chemotherapy after a celecoxib-induced hypersensitivity reaction. ( Burbach, GJ; Vajkoczy, P; Zuberbier, T, 2012)
"Only a few studies examined the effect of temozolomide (TMZ) in recurrent low-grade astrocytoma (LGA) after surgery, none of which included a homogeneous and sufficiently sized group of patients with progression after radiotherapy (RT)."	3.77	First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. ( Boogerd, W; Bromberg, JE; Dinjens, WN; Dubbink, HJ; Gijtenbeek, JM; Groenendijk, FH; Kouwenhoven, MC; Kros, JM; Postma, TJ; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Holt, B; van Heuvel, I; van Marion, R; Zonnenberg, BA; Zonnenberg, CB, 2011)
"The aim of the present study was to investigate the kinetics of the effects exerted by Temodal and quercetin on the survival of the human astrocytoma MOGGCCM cell line."	3.77	Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells. ( Jakubowicz-Gil, J; Langner, E; Rzeski, W, 2011)
"Temozolomide, an oral alkylating agent, is a commonly used medicine in the treatment of anaplastic astrocytoma and glioblastoma multiforme."	3.76	Temozolomide (Temodar). ( Mukherji, SK; Rajdev, P; Wesolowski, JR, 2010)
"The aim of the present study was to investigate the effect of Temozolomide (an alkylating chemotherapeutic agent) and quercetin (natural flavonoid) on cell death in the human astrocytoma cell line MOGGCCM (WHO grade III)."	3.76	Temozolomide, quercetin and cell death in the MOGGCCM astrocytoma cell line. ( Jakubowicz-Gil, J; Langner, E; Piersiak, T; Rzeski, W; Wertel, I, 2010)
"We present a case of a 12-year-old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ)."	3.76	Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. ( Hosono, A; Makimoto, A; Miyakita, Y; Momota, H; Nariata, Y; Narita, Y; Shibui, S, 2010)
"Temozolomide is an oral alkylating agent approved for the treatment of glioblastoma and anaplastic astrocytoma, and is currently under clinical investigation for the treatment of brain metastases from a variety of cancers."	3.76	Urticarial hypersensitivity reaction caused by temozolomide. ( Hsu, MY; Ibrahimi, OA; Kesari, S; Pothiawala, S; Yang, C, 2010)
"Temozolomide (TMZ) is an alkylating agent used in the management of gliomas."	3.75	Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? ( Bell, D; Khasraw, M; Wheeler, H, 2009)
" In this study, the authors investigate the nature of the SP phenotype in 2 glioma cell lines, U87MG and T98G, and their response to temozolomide."	3.74	Characterization of a side population of astrocytoma cells in response to temozolomide. ( Ang, BT; Chong, KH; Chua, C; See, SJ; Tang, C; Wong, MC; Zaiden, N, 2008)
"Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival."	3.74	Fatal outcome related to carmustine implants in glioblastoma multiforme. ( Barcia, JA; Barcia-Mariño, C; Gallego, JM, 2007)
"To develop a valid treatment strategy for recurrent high-grade gliomas using stereotactic hypofractionated reirradiation based on biologic imaging and temozolomide."	3.73	Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. ( Franz, M; Grosu, AL; Gumprecht, H; Molls, M; Nieder, C; Piert, M; Schwaiger, M; Stärk, S; Thamm, R; Weber, WA, 2005)
"p53 inactivation sensitizes U87MG astrocytic glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and temozolomide (TMZ), drugs used clinically to treat high-grade astrocytomas."	3.73	Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin. ( Cairncross, JG; Mymryk, JS; Xu, GW, 2005)
"We compared survival in patients with anaplastic astrocytoma (AA) treated with adjuvant procarbazine, lomustine, and vincristine (PCV) with survival in patients treated with temozolomide."	3.73	Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. ( Brandes, AA; Ermani, M; Gardiman, M; Ghimenton, C; Iuzzolino, P; Nicolardi, L; Reni, M; Rotilio, A; Sotti, G; Tosoni, A, 2006)
"To assess whether the survival of patients with recurrent malignant glioma receiving temozolomide in everyday practice is comparable to that reported in previous studies."	3.72	Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. ( Maltoni, S; Messori, A; Pelagotti, F; Trippoli, S; Vacca, F; Vaiani, M, 2003)
"Patients with newly diagnosed anaplastic astrocytoma (AA) or anaplastic oligo-astrocytoma (AOA) were treated with concurrent radiotherapy (60 Gy over 6 weeks) and temozolomide (75 mg/m(2)), and six adjuvant 28-day cycles of either dose-dense (150 mg/m(2), days 1-7, 15-21) or metronomic (50 mg/m(2), days 1-28) temozolomide."	2.80	Radiotherapy and temozolomide for anaplastic astrocytic gliomas. ( Abrey, LE; Braunthal, SG; DeAngelis, LM; Huse, JT; Lassman, AB; Nayak, L; Panageas, KS; Pentsova, E; Reiner, AS, 2015)
"Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable, and large field radiotherapy carries the risk of severe toxicity."	2.71	Initial chemotherapy in gliomatosis cerebri. ( Carpentier, A; Cartalat-Carel, S; Chinot, O; Cougnard, J; Delattre, JY; Djafari, L; Duffau, H; Gervais, H; Hoang-Xuan, K; Honnorat, J; Laigle, F; Mokhtari, K; Napolitano, M; Sanson, M; Taillandier, L; Taillibert, S, 2004)
"The optimal therapy for gliomatosis cerebri is unclear, and the rate of response to chemotherapy is not known."	2.71	Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. ( Gomori, JM; Levin, N; Siegal, T, 2004)
"We conducted a study to determine the dose-limiting toxicity of an extended dosing schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), taking advantage of TMZ's ability to deplete O6-alkylguanine-DNA-alkyltransferase and the synergistic activity of these two agents."	2.71	Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. ( Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004)
" The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days."	2.70	Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. ( Affronti, ML; Cokgor, L; Early, M; Edwards, S; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S, 2001)
"Temozolomide was well tolerated with little subjective toxicity and usually predictable myelosuppression and is a promising new drug in the treatment of primary brain tumours."	2.67	Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. ( Brampton, M; Colquhoun, IR; Glaser, MG; Illingworth, RD; Kennard, C; Lewis, P; Newlands, ES; O'Reilly, SM; Rice-Edwards, JM; Richards, PG, 1993)
"Glioblastoma multiforme is the most common and most lethal pri- mary malignant tumor of the central nervous system."	2.50	Astrocytoma malignum in glioblastoma multiforme vertens with long term survival--case report and a literature review. ( Bochenek-Cibor, J; Krupa, M; Moskała, M; Trojanowski, T, 2014)
"Temozolomide is a new drug which has shown promise in treating malignant gliomas and other difficult-to-treat tumors."	2.45	Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. ( Beli, I; Chaldeopoulos, D; Fotineas, A; Koukourakis, GV; Kouloulias, V; Kouvaris, J; Maravelis, G; Pantelakos, P; Papadimitriou, C; Zacharias, G, 2009)
"Temozolomide is an oral alkylating cytotoxic agent of second generation, used in the treatment of high-grade gliomas."	2.45	[Prescription guidebook for temozolomide usage in brain tumors]. ( Borget, I; Brignone, M; Cartalat-Carel, S; Chinot, O; Hassani, Y; Taillandier, L; Taillibert, S; Tilleul, P, 2009)
"High-grade gliomas (WHO grade III anaplastic astrocytoma and grade IV glioblastoma multiforme) are the most common primary tumors in the central nervous system in adults."	2.45	High-grade glioma mouse models and their applicability for preclinical testing. ( Beijnen, JH; de Vries, NA; van Tellingen, O, 2009)
"Anaplastic astrocytoma is an uncommon disease in the adult population."	2.44	Anaplastic astrocytoma in adults. ( Gatta, G; Mazza, E; Reni, M; Stupp, R; Vecht, C, 2007)
"Leptomeningeal dissemination of juvenile pilocytic astrocytoma (JPA) is a rare event."	2.43	Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature. ( Aryan, HE; Bruce, DA; Levy, ML; Lu, DC; Meltzer, HS; Ozgur, BM, 2005)
"Astrocytomas are the most common primary brain tumors."	2.43	Treatment of astrocytomas. ( Gilbert, MR; Gonzalez, J, 2005)
"Temozolomide was effective in delaying disease progression and maintaining health-related quality of life."	2.41	Temozolomide in malignant gliomas. ( Yung, WK, 2000)
"Temozolomide is a novel, oral, second-generation alkylating agent."	2.41	Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. ( Friedman, HS, 2000)
"Temozolomide, a new drug, has shown promise in treating malignant gliomas and other difficult-to-treat tumors."	2.41	Temozolomide and treatment of malignant glioma. ( Calvert, H; Friedman, HS; Kerby, T, 2000)
" For patients with recurrent malignant glioma, temozolomide provides a therapeutic option with a predictable safety profile, clinical efficacy, and convenient dosing that can provide important quality-of-life benefits."	2.41	Temozolomide for recurrent high-grade glioma. ( Macdonald, DR, 2001)
"Temozolomide appears to produce few serious adverse effects and may also have a positive impact on health-related quality of life."	2.41	A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. ( Cave, C; Dinnes, J; Huang, S; Milne, R, 2002)
"Diffuse gliomas are a heterogeneous category of primary central nervous system tumors."	1.91	Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences. ( Baird, L; Beadling, C; Corless, C; Harrington, CA; Moore, S; Neff, T; Wood, MD, 2023)
"Temozolomide (TMZ) was given to 24 patients and 11 patients received TMZ plus other chemotherapies."	1.91	The effect of chemotherapies on the crosstalk interaction between CD8 cytotoxic T-cells and MHC-I peptides in the microenvironment of WHO grade 4 astrocytoma. ( Alkhayyat, S; Alkhotani, A; Almansouri, M; Alshanqiti, M; Alsinani, T; Baeesa, S; Bamaga, AK; Butt, N; Enani, M; Fadul, MM; Faizo, E; Hassan, A; Karami, MM; Kurdi, M, 2023)
"Glioblastoma is the most common brain tumor."	1.72	( Balkanov, AS; Belyaev, AY; Glazkov, AA; Kobyakov, GL; Rozanov, ID; Shmakov, PN; Strunina, YV; Telysheva, EN; Usachev, DY, 2022)
"Human glioblastoma is a malignant and aggressive primary human brain solid tumor characterized by severe hypoxia."	1.51	The HIF‑1α/miR‑224‑3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia‑induced protective autophagy in glioblastoma and astrocytoma. ( He, X; Huang, S; Li, F; Qi, P; Zhang, T, 2019)
"Tremor is the most prevalent movement disorder."	1.48	Tremor Secondary to a Thalamic Glioma: A Case Report. ( Elias, WJ; Fadul, CE; Wang, TR, 2018)
"Glioblastoma (GBM) is a grade IV astrocytoma."	1.46	Glioblastoma entities express subtle differences in molecular composition and response to treatment. ( Balça-Silva, J; Canedo, NHS; Correia, AH; De Souza, JM; Do Carmo, A; Dubois, LG; Girão, H; Gonçalves, AC; Lopes, MC; Matias, D; Moura-Neto, V; Sarmento-Ribeiro, AB, 2017)
"A 43-year-old man with an anaplastic astrocytoma received radiation therapy synchronized with ranimustine and adjuvant TMZ chemotherapy for 15 cycles."	1.46	A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma. ( Kosugi, K; Saito, K; Takahashi, W; Tokuda, Y; Tomita, H, 2017)
"The study included 26 patients with anaplastic astrocytoma and 37 patients with glioblastoma; all patients were aged ≤18 years."	1.43	High-grade glioma in children and adolescents: a single-center experience. ( Akalan, N; Akyuz, C; Cengiz, M; Eren, G; Gurkaynak, M; Ozyigit, G; Varan, A; Yazici, G; Yüce, D; Zorlu, F, 2016)
"Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14."	1.43	Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. ( Ajit, NE; Burton, GV; El-Osta, H; Peddi, P, 2016)
"The treatment of anaplastic astrocytoma (AA) is controversial."	1.40	Chemotherapeutic resistance in anaplastic astrocytoma cell lines treated with a temozolomide-lomeguatrib combination. ( Canpinar, H; Castresana, JS; Ilgaz, S; Rey, JA; Sert, F; Sunguroglu, A; Taspinar, M; Ugur, HC, 2014)
"One patient with anaplastic ganglioglioma experienced confirmed partial tumor response and significant clinical improvement and she is alive 20 months after start of treatment."	1.40	Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. ( Bautista, F; Dufour, C; Geoerger, B; Grill, J; Lacroix, L; Minard-Colin, V; Paci, A; Valteau-Couanet, D; Varlet, P, 2014)
"Temozolomide was used almost exclusively during CRT (94."	1.39	Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. ( Cahill, D; Gilbert, MR; Lei, X; Shonka, NA; Smith, L; Theeler, B; Yung, A, 2013)
"Low-grade gliomas (e."	1.39	Cerebellar anaplastic astrocytoma in an adult with neurofibromatosis type 1: case report and review of literature. ( Brokinkel, B; Ewelt, C; Hargus, G; Heindel, W; Holling, M; Schober, O; Stummer, W; Wölfer, J, 2013)
"Temozolomide (TMZ) is an alkylating agent primarily used to treat tumors of the central nervous system."	1.39	Central diabetes insipidus: a previously unreported side effect of temozolomide. ( Faje, AT; Klibanski, A; Makimura, H; Miller, KK; Nachtigall, L; Wexler, D, 2013)
"The tumor was partially resected and anaplastic astrocytoma was diagnosed."	1.38	Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis. ( Fujimoto, Y; Hashimoto, N; Kagawa, N; Kinoshita, M; Miyazaki, Y; Takehara, T; Tanaka, S; Yakushijin, T; Yoshimine, T, 2012)
"Compared with pilocytic astrocytoma, PMA is more aggressive, has a higher rate of local recurrence, and often disseminates to the leptomeninges."	1.38	Successful treatment of leptomeningeal gliomatosis of pilomyxoid astrocytoma after failed frontline chemotherapy. ( Bouffet, E; Maeda, M; Morioka, M; Sawamura, Y; Sugita, Y; Terasaki, M, 2012)
"Histological examination revealed anaplastic astrocytoma."	1.38	Radiation-induced spinal cord anaplastic astrocytoma subsequent to radiotherapy for testicular seminoma. ( Hoshimaru, M; Kawanabe, Y; Kihara, S; Koizumi, T; Sasaki, N; Sawada, M; Ueda, S; Yukawa, H, 2012)
"Temozolomide is an effective treatment for seizure control in patients with brain tumors."	1.37	Seizure control: a secondary benefit of chemotherapeutic temozolomide in brain cancer patients. ( Hu, A; Kesari, S; Kim, RY; Lee, JW; Nguyen, A; Xu, Z, 2011)
" The aim of the present study was to evaluate the efficacy and side effects of nimotuzumab in combination with chemotherapy for patients with malignant gliomas."	1.37	[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas]. ( Chen, ZP; Jiang, XB; Mu, YG; Sai, K; Shen, D; Yang, QY; Zhang, XH, 2011)
"Temozolomide is a relatively new chemotherapeutic agent frequently associated with selective CD4+ T-lymphocytopenia."	1.35	Disseminated salmonellosis in a patient treated with temozolomide. ( Adachi, J; Georgescu, G; Isola, IM; Rolston, K; Youssef, S, 2008)
"For patients with anaplastic astrocytoma, the 12-month survival rate was 73%."	1.34	Salvage chemotherapy in progressive high-grade astrocytoma. ( See, SJ; Ty, A; Wong, MC, 2007)
"Temozolomide was administered at a dose of 200 mg/m(2) daily for 5 days, in a 4-week cycle."	1.34	Temozolomide in pediatric low-grade glioma. ( Ashley, DM; Coleman, LT; Downie, PA; Heath, JA; Khaw, SL, 2007)
"At the time of the initial disease recurrence, 13 patients were readministered TMZ."	1.33	Salvage temozolomide for prior temozolomide responders. ( Abrey, LE; Demopoulos, A; Franceschi, E; Lassman, AB; Nolan, C; Omuro, AM, 2005)
"Grosstotal resection of an anaplastic astrocytoma was followed by chemotherapy with temozolomide and vincristine."	1.33	A congenital brain tumor associated with assisted in vitro fertilization. Case report. ( Danielpour, M; Das, A; Simmons, C, 2005)

Research

Studies (197)

Authors

Clinical Trials (19)

Trial Overview

Trial Outcomes

Overall Survival as Measured From the Day of Randomization

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (3.55)	18.2507
2000's	74 (37.56)	29.6817
2010's	91 (46.19)	24.3611
2020's	25 (12.69)	2.80

Authors	Studies
Tesileanu, CMS	2
Gorlia, T	2
Golfinopoulos, V	2
French, PJ	2
van den Bent, MJ	7
Sanson, M	3
Wick, W	4
Brandes, AA	3
Clement, PM	1
Erridge, SC	1
Vogelbaum, MA	2
Nowak, AK	1
Baurain, JF	1
Mason, WP	1
Wheeler, H	3
Chinot, OL	3
Gill, S	1
Griffin, M	1
Rogers, L	1
Taal, W	3
Rudà, R	1
Weller, M	4
McBain, C	1
van Linde, ME	1
Aldape, K	1
Jenkins, RB	2
Kros, JM	5
Wesseling, P	1
von Deimling, A	2
Hoogstrate, Y	1
de Heer, I	1
Atmodimedjo, PN	1
Dubbink, HJ	3
Brouwer, RWW	1
van IJcken, WFJ	1
Cheung, KJ	1
Baumert, BG	1
Tom, MC	1
Milano, MT	1
Chao, ST	1
Soltys, SG	1
Knisely, JPS	1
Sahgal, A	1
Nagpal, S	1
Lo, SS	1
Jabbari, S	1
Wang, TJC	1
Ahluwalia, MS	1
Simonson, M	1
Palmer, JD	1
Gephart, MH	1
Halasz, LM	1
Garg, AK	1
Chiang, VLS	1
Chang, EL	1
Feldheim, J	1
Kessler, AF	1
Feldheim, JJ	1
Schulz, E	1
Wend, D	1
Lazaridis, L	1
Kleinschnitz, C	1
Glas, M	2
Ernestus, RI	1
Brandner, S	2
Monoranu, CM	1
Löhr, M	1
Hagemann, C	1
Jo, J	1
Schiff, D	3
Weller, J	1
Katzendobler, S	1
Blobner, J	1
Thiele, F	1
Becker, H	1
Quach, S	1
Egensperger, R	1
Niyazi, M	1
Suchorska, B	1
Thon, N	1
Tonn, JC	1
Balkanov, AS	1
Rozanov, ID	1
Glazkov, AA	1
Belyaev, AY	1
Kobyakov, GL	1
Shmakov, PN	1
Telysheva, EN	1
Strunina, YV	1
Usachev, DY	1
Minniti, G	2
Paolini, S	1
Antonelli, M	1
Gianno, F	1
Tini, P	1
Lanzetta, G	2
Arcella, A	2
De Pietro, R	1
Giraffa, M	1
Capone, L	1
Romano, A	1
Bozzao, A	2
Esposito, V	2
Wood, MD	1
Beadling, C	1
Neff, T	1
Moore, S	1
Harrington, CA	1
Baird, L	1
Corless, C	1
Butt, N	1
Enani, M	1
Alshanqiti, M	1
Alkhotani, A	1
Alsinani, T	1
Karami, MM	1
Fadul, MM	1
Almansouri, M	1
Hassan, A	1
Baeesa, S	1
Bamaga, AK	1
Alkhayyat, S	1
Faizo, E	1
Kurdi, M	1
Rautajoki, KJ	1
Jaatinen, S	1
Hartewig, A	1
Tiihonen, AM	1
Annala, M	1
Salonen, I	1
Valkonen, M	1
Simola, V	1
Vuorinen, EM	1
Kivinen, A	1
Rauhala, MJ	1
Nurminen, R	1
Maass, KK	1
Lahtela, SL	1
Jukkola, A	1
Yli-Harja, O	1
Helén, P	1
Pajtler, KW	1
Ruusuvuori, P	1
Haapasalo, J	1
Zhang, W	1
Haapasalo, H	2
Nykter, M	2
Vaz Salgado, MA	1
Torres, J	1
Esteban, J	1
Gutiérrez, JA	1
Ley, L	1
Carrato, A	1
Wick, A	1
Kessler, T	1
Platten, M	2
Meisner, C	2
Bamberg, M	1
Herrlinger, U	2
Felsberg, J	2
Weyerbrock, A	1
Papsdorf, K	2
Steinbach, JP	3
Sabel, M	2
Vesper, J	2
Debus, J	2
Meixensberger, J	2
Ketter, R	2
Hertler, C	1
Mayer-Steinacker, R	2
Weisang, S	1
Bölting, H	1
Reuss, D	1
Reifenberger, G	2
Sahm, F	1
Candido, MF	1
Baldissera, GC	1
Medeiros, M	1
Umezawa, K	1
Brassesco, MS	1
Roberts, TA	1
Hyare, H	1
Agliardi, G	1
Hipwell, B	1
d'Esposito, A	1
Ianus, A	1
Breen-Norris, JO	1
Ramasawmy, R	1
Taylor, V	1
Atkinson, D	1
Punwani, S	1
Lythgoe, MF	1
Siow, B	1
Rees, J	1
Panagiotaki, E	1
Alexander, DC	1
Walker-Samuel, S	1
Yang, D	1
Cheng, X	1
Bu, X	1
Yan, Z	1
Wu, T	1
Zhang, Y	2
Bhawe, K	1
Felty, Q	1
Yoo, C	1
Ehtesham, NZ	1
Hasnain, SE	1
Singh, VP	1
Mohapatra, I	1
Roy, D	1
White, ML	1
Kazmi, SAJ	1
Aizenberg, M	1
Shonka, N	1
Yu, F	1
Appiah, AK	1
Esteyrie, V	1
Dehais, C	1
Martin, E	1
Carpentier, C	1
Uro-Coste, E	1
Figarella-Branger, D	2
Bronniman, C	1
Pouessel, D	1
Ciron, DL	1
Ducray, F	1
Moyal, EC	1
Network, P	1
Wu, J	1
Yuan, Y	1
Long Priel, DA	1
Fink, D	1
Peer, CJ	1
Sissung, TM	1
Su, YT	1
Pang, Y	1
Yu, G	1
Butler, MK	1
Mendoza, TR	1
Vera, E	1
Ahmad, S	1
Bryla, C	1
Lindsley, M	1
Grajkowska, E	1
Mentges, K	1
Boris, L	1
Antony, R	1
Garren, N	1
Siegel, C	1
Lollo, N	1
Cordova, C	1
Aboud, O	1
Theeler, BJ	1
Burton, EM	1
Penas-Prado, M	2
Leeper, H	1
Gonzales, J	1
Armstrong, TS	1
Calvo, KR	1
Figg, WD	1
Kuhns, DB	1
Gallin, JI	1
Gilbert, MR	4
Guo, Z	1
Li, D	1
Xie, Y	1
Qian, J	1
Zhao, B	1
Filppu, P	1
Tanjore Ramanathan, J	1
Granberg, KJ	1
Gucciardo, E	1
Lehti, K	1
Le Joncour, V	1
Laakkonen, P	1
Sasaki, H	1
Anand, S	1
Chatterjee, A	1
Gupta, T	1
Panda, P	1
Moiyadi, A	1
Epari, S	1
Patil, V	1
Krishnatry, R	1
Goda, JS	1
Jalali, R	1
Marucci, G	1
Chang, SM	4
Chakavarti, A	1
Bell, EH	2
Carroll, KT	1
Hirshman, B	1
Ali, MA	1
Alattar, AA	1
Brandel, MG	1
Lochte, B	1
Lanman, T	1
Carter, B	1
Chen, CC	1
Trogrlić, I	1
Trogrlić, D	1
Trogrlić, Z	1
Jakubowicz-Gil, J	4
Bądziul, D	2
Langner, E	4
Wertel, I	3
Zając, A	1
Rzeski, W	4
Balça-Silva, J	1
Matias, D	1
Do Carmo, A	1
Dubois, LG	1
Gonçalves, AC	1
Girão, H	1
Canedo, NHS	1
Correia, AH	1
De Souza, JM	1
Sarmento-Ribeiro, AB	1
Lopes, MC	1
Moura-Neto, V	1
Zhou, Z	1
Howard, TA	1
Villano, JL	1
Takai, K	1
Tanaka, S	3
Sota, T	1
Mukasa, A	1
Komori, T	1
Taniguchi, M	1
Chaskis, E	1
Minichini, V	1
Luce, S	1
Devriendt, D	1
Goldman, S	1
De Witte, O	1
Sadeghi, N	1
Lefranc, F	1
Wang, TR	1
Fadul, CE	1
Elias, WJ	1
Hayashi, S	1
Akao, N	1
Nakazato, Y	1
Okamoto, K	1
Puduvalli, VK	1
Hoang, N	1
Narita, Y	2
Wang, HC	1
Lin, YT	1
Lin, WC	1
Ho, RW	1
Lin, YJ	1
Tsai, NW	1
Ho, JT	2
Lu, CH	1
Wei, J	1
Yang, G	1
Hao, X	1
Gu, D	1
Tan, Y	1
Wang, X	1
Dong, D	1
Zhang, S	1
Wang, L	1
Zhang, H	1
Tian, J	1
Fortunato, JT	1
Reys, B	1
Singh, P	1
Pan, E	1
Thompson, EM	1
Landi, D	1
Ashley, D	1
Keir, ST	1
Bigner, D	1
Huang, S	2
Qi, P	1
Zhang, T	1
Li, F	1
He, X	1
Aghajan, Y	1
Malicki, DM	1
Levy, ML	2
Crawford, JR	1
Back, M	1
Jayamanne, D	1
Brazier, D	1
Newey, A	1
Bailey, D	1
Schembri, G	1
Hsiao, E	1
Khasraw, M	2
Wong, M	1
Kastelan, M	1
Brown, C	1
Carabenciov, ID	1
Bhargav, AG	1
Uhm, JH	3
Ruff, MW	1
Katayama, K	1
Asano, K	1
Shimamura, N	1
Ogasawara, Y	1
Naraoka, M	1
Ohkuma, H	1
Kurose, A	1
Shonka, NA	1
Theeler, B	1
Cahill, D	1
Yung, A	1
Smith, L	1
Lei, X	1
Sun, J	1
Yang, XJ	1
Yang, SY	1
Brokinkel, B	1
Schober, O	1
Ewelt, C	1
Heindel, W	1
Hargus, G	1
Stummer, W	1
Holling, M	1
Wölfer, J	1
Faje, AT	1
Nachtigall, L	1
Wexler, D	1
Miller, KK	1
Klibanski, A	1
Makimura, H	1
Takeshi, N	1
Kazuhiko, S	1
Koji, I	1
Toshikazu, H	1
Kaoru, K	1
Habets, EJ	1
Taphoorn, MJ	2
Nederend, S	1
Klein, M	1
Delgadillo, D	1
Hoang-Xuan, K	3
Bottomley, A	1
Allgeier, A	2
Seute, T	1
Gijtenbeek, AM	1
de Gans, J	1
Enting, RH	3
Tijssen, CC	1
Reijneveld, JC	1
Ugur, HC	1
Taspinar, M	1
Ilgaz, S	1
Sert, F	1
Canpinar, H	1
Rey, JA	1
Castresana, JS	1
Sunguroglu, A	1
Bautista, F	1
Paci, A	1
Minard-Colin, V	1
Dufour, C	1
Grill, J	1
Lacroix, L	1
Varlet, P	1
Valteau-Couanet, D	1
Geoerger, B	1
Capdevila, L	1
Cros, S	1
Ramirez, JL	1
Sanz, C	1
Carrato, C	1
Romeo, M	1
Etxaniz, O	1
Hostalot, C	1
Massuet, A	1
Cuadra, JL	1
Villà, S	1
Balañà, C	1
Scaringi, C	1
Di Stefano, D	1
Scarpino, S	1
Pace, A	2
Villani, V	2
Salvati, M	1
Giangaspero, F	1
Enrici, RM	1
Kizilbash, SH	1
Giannini, C	2
Voss, JS	1
Decker, PA	1
Hardie, J	1
Laack, NN	2
Parney, IF	2
Buckner, JC	3
Voellger, B	1
Tapia-Perez, JH	1
Rupa, R	1
Karagiannis, D	1
Mawrin, C	1
Kirches, E	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial.[NCT00626990]	Phase 3	751 participants (Actual)	Interventional	2007-12-31	Active, not recruiting
Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem)[NCT01502241]	Phase 3	412 participants (Actual)	Interventional	2005-01-31	Completed
A Phase I/II Study of Zotiraciclib for Recurrent High-Grade Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations[NCT05588141]	Phase 1/Phase 2	96 participants (Anticipated)	Interventional	2023-05-16	Recruiting
A Phase II Trial Of Pre-Irradiation And Concurrent Temozolomide In Patients With Newly Diagnosed Anaplastic Oligodendrogliomas And Mixed Anaplastic Oligoastrocytomas[NCT00033280]	Phase 2	42 participants (Actual)	Interventional	2002-07-31	Completed
Temozolomide Plus Bevacizumab Chemotherapy in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status (KPS<70)[NCT02898012]	Phase 2	70 participants (Actual)	Interventional	2010-10-31	Completed
A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients[NCT01819233]		38 participants (Actual)	Interventional	2013-03-08	Completed
Can Fasting Decrease the Side Effects of Chemotherapy?[NCT04027478]		39 participants (Anticipated)	Interventional	2019-09-01	Enrolling by invitation
A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant)[NCT00004259]	Phase 3	230 participants (Actual)	Interventional	2000-06-30	Completed
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793]	Phase 2	11 participants (Actual)	Interventional	2010-10-14	Terminated (stopped due to The clinical trial was terminated due to poor enrollment)
A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595]	Phase 2	0 participants (Actual)	Interventional	2009-02-28	Withdrawn (stopped due to No patients accrued since study opened)
Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme - a Randomised Phase II Trial[NCT01252459]	Phase 2	200 participants (Anticipated)	Interventional	2011-07-31	Not yet recruiting
Role of Repeat Resection in Recurrent Glioblastoma (4rGBM) Trial: a Randomized Care Trial for Patients With Recurrent GBM[NCT04838782]		250 participants (Anticipated)	Interventional	2021-08-26	Recruiting
A Phase II Study in Relapsing Glioblastoma of Intraarterial Concurrent Chemoradiation Therapy Using IA Carboplatin[NCT03672721]	Phase 1/Phase 2	35 participants (Anticipated)	Interventional	2018-07-10	Recruiting
A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma[NCT00028795]	Phase 2	170 participants (Actual)	Interventional	2002-12-31	Completed
An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway[NCT01601184]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2012-06-30	Terminated (stopped due to The number of successes is not reached at the end of first stage of the phase II. The study is stopped.)
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas[NCT01837862]	Phase 1/Phase 2	36 participants (Anticipated)	Interventional	2013-10-22	Recruiting
Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075]	Phase 2	25 participants (Actual)	Interventional	2002-07-31	Completed
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors[NCT00994071]	Phase 1	9 participants (Actual)	Interventional	2009-09-22	Completed
The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial[NCT01847235]	Phase 2	23 participants (Actual)	Interventional	2013-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The duration of survival is the time interval between randomization and the date of death due to any cause. Patients not reported dead or lost to follow up will be censored at the date of the last follow up examination. (NCT00626990)
Timeframe: from date from enrollment till the date of death (time till death is up to 10.9 years after patient enrollment in the study)

Progression-free Survival

Intervention	Months (Median)
Absence of Concomitant Temozolomide (TMZ)	60.42
Presence of Concomitant Temozolomide (TMZ)	66.92
Absence of Adjuvant Temozolomide (TMZ)	46.92
Presence of Adjuvant Temozolomide (TMZ)	82.33

Disease progression is defined as radiological or neurological/clinical progression (whichever occurs first); progression free survival (PFS) is the time interval between the date of randomization and the date of disease progression or death whichever occurs first. If neither event has been observed, the patient is censored at the date of the last follow up examination. Radiological progression was defined as increase of contrast enhancing area on MRI or CT scans of more than 25% as measured by two perpendicular diameters compared to the smallest measurements ever recorded for the same lesion by the same technique. The appearance of new lesions with or without contrast enhancement Neurological/clinical progression was defined as:decrease in WHO performance status,deterioration of neurological functions,appearance of signs/symptoms of increased intracranial pressure,and/or start of corticosteroid or increase of corticosteroid dosage by 50% for control of neurological symptoms. (NCT00626990)
Timeframe: from randomization till the date of disease progression or death (time till death is up to 10.9 years after patient enrollment in the study)

Change in Body Fat Measurement

Intervention	Months (Median)
Absence of Concomitant TMZ	20.9
Presence of Concomitant TMZ	33.02
Absence of Adjuvant TMZ	19.09
Presence of Adjuvant TMZ	42.81

Analyzed via a paired t-test. Change in body fat measurement as determined by the Durnin-Womersley 4-fold technique (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study

Change in Body Mass Index (BMI)

Intervention	percentage of change in body fat (Mean)
Behavioral Dietary Intervention	-3.1

Assessed via mixed-effects regression. Weight changes over time assessed by modeling BMI as a function of time (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study

Change in Heart Rate Over Time

Intervention	percentage of change in BMI (Mean)
Behavioral Dietary Intervention	-1.2

Assessed via mixed-effects regression. (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study

Distant Metastases

Intervention	beats per minute (Mean)
Behavioral Dietary Intervention	67.3

Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study

Local Recurrence

Intervention	Participants (Count of Participants)
Behavioral Dietary Intervention	NA

Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study

Number of Participants Who Are Adherent to the Diet Restriction

Intervention	Participants (Count of Participants)
Behavioral Dietary Intervention	NA

Computed along with a 95% exact confidence interval. Exact binomial test (with a one-sided alpha of 0.05) will be used to test whether adherence is greater than 60%. (NCT01819233)
Timeframe: Up to week 12

Overall Survival

Intervention	participants (Number)
Behavioral Dietary Intervention	28

Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study

Patterns of Change Over Time in Psycho-social Outcomes Measured Using the Functional Assessment of Cancer Therapy-Breast (FACT-B)

Intervention	Participants (Count of Participants)
Behavioral Dietary Intervention	NA

Assessed via mixed-effects regression. The FACT-B is a questionnaire using a 5-point Likert scale (0-Not at all to 4-Very much) (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study

Progression Free Survival

Intervention	score on a scale (Mean)
Behavioral Dietary Intervention	0.8

Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study

(Phase III) Overall Survival (OS)

Intervention	Participants (Count of Participants)
Behavioral Dietary Intervention	NA

Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Per the protocol, the pilot arms were not included in the Phase III analyses. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.

(Phase III) Progression-free Survival by MGMT Status

Intervention	years (Median)
Radiation Therapy + Temozolomide (TMZ)	3.9
RT + BCNU/CCNU	3.8

Progression is defined as a radiographic increase in size of the lesion by > 25%, recurrence of the study lesion, or the development of new lesions, confirmed by imaging. Progression-free survival time is defined as time from randomization to date of progression or death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Tumor tissue samples were analyzed for methylation status of methyl guanine methyl transferase (MGMT), classified as methylated vs. unmethylated. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.

(Phase III) Survival Time by MGMT Status

Intervention	years (Median)
Methylated MGMT	4.0
Unmthylated MGMT	2.1

Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Tumor tissue samples were analyzed for methylation status of methyl guanine methyl transferase (MGMT), classified as methylated vs. unmethylated. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.

(Phase III) Time to Tumor Progression (TTP)

Intervention	years (Median)
Methylated MGMT	7.2
Unmthylated MGMT	3.1

Three-year rate is reported. Progression is defined as a radiographic increase in size of the lesion by > 25%, recurrence of the study lesion, or the development of new lesions, confirmed by imaging. Time to tumor progression was estimated using the cumulative incidence function (CIF) on tumor progression, with death as a competing risk. Per the protocol, the pilot arms were not included in the Phase III analyses. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.

(Phase I) Number of Subjects With Dose Limiting Toxicities (DLT) on the Two Pilot Arms

Intervention	months (Median)
Radiation Therapy + Temozolomide (TMZ)	45.4
RT + BCNU/CCNU	54.7

Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the adverse event (AE). The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. Dose limiting toxicity (DLT) was defined as grade 3+ pulmonary toxicity, grade 4+ thrombocytopenia (< 25,000 for 5 days), neutropenia (< 500/microl for 7 days), or neutropenia of any duration with fever requiring hospital admission after one dose reduction of 50% in BCNU. A 20% rate of grade 3+ pulmonary toxicities or a 40% rate of grade 4+ thrombocytopenia and neutropenia was considered unacceptable for a treatment arm combining RT, TMZ, and BCNU. (NCT00004259)
Timeframe: From start of treatment to 3 months

(Phase III) Number of Patients With Grade 3 or Higher Toxicity

Intervention	Participants (Count of Participants)
	Subjects with Pulmonary DLT	Subjects with Hematologic DLT
Pilot Arm #1: RT+TMZ+BCNU	1	4
Pilot Arm #2: RT+TMZ+BCNU	0	3

Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the AE. The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. The number of patients with grade or higher toxicity was calculated overall and for non-hematologic toxicity only. Per the protocol, the pilot arms were not included in the Phase III analyses. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.

Safest Dose of Temozolomide for the DRBEAT Regimen

Intervention	participants (Number)
	Overall toxicity	Non-hematologic toxicity
Radiation Therapy + Temozolomide (TMZ)	46	31
RT + BCNU/CCNU	75	34

Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year

One-year Progression-free Survival and Overall Survival

Intervention	dose in mg/m^2 (Number)
DRBEAT Regimen	773.25

"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years

Overall Survival

Percentage of Participants With Distant Brain Failure (DBF) at One Year

Intervention	Days (Median)
	Progression Free Survival	Overall Survival
DRBEAT Regimen	132	564

Intervention	weeks (Median)
Radiosurgery 15-24 Gy + Adjuvant Temozolomide	31

Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years

temozolomide and Astrocytoma

Research Excerpts

Research

Studies (197)

Authors

Clinical Trials (19)

Trial Overview

Trial Outcomes

Overall Survival as Measured From the Day of Randomization

Progression-free Survival

Change in Body Fat Measurement

Change in Body Mass Index (BMI)

Change in Heart Rate Over Time

Distant Metastases

Local Recurrence

Number of Participants Who Are Adherent to the Diet Restriction

Overall Survival

Patterns of Change Over Time in Psycho-social Outcomes Measured Using the Functional Assessment of Cancer Therapy-Breast (FACT-B)

Progression Free Survival

(Phase III) Overall Survival (OS)

(Phase III) Progression-free Survival by MGMT Status

(Phase III) Survival Time by MGMT Status

(Phase III) Time to Tumor Progression (TTP)

(Phase I) Number of Subjects With Dose Limiting Toxicities (DLT) on the Two Pilot Arms

(Phase III) Number of Patients With Grade 3 or Higher Toxicity

Safest Dose of Temozolomide for the DRBEAT Regimen

One-year Progression-free Survival and Overall Survival

Overall Survival

Percentage of Participants With Distant Brain Failure (DBF) at One Year

Reviews

Trials

Other Studies

Article	Year
Executive summary of American Radium Society's appropriate use criteria for the postoperative management of lower grade gliomas. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022, Volume: 170 Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Oligodendroglioma; Radium; Temozolomide	2022
Executive summary of American Radium Society's appropriate use criteria for the postoperative management of lower grade gliomas. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022, Volume: 170 Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Oligodendroglioma; Radium; Temozolomide	2022
Current Considerations in the Treatment of Grade 3 Gliomas. Current treatment options in oncology, 2022, Volume: 23, Issue:9 Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Lymphoma, Follicular; Mutati	2022
Current Considerations in the Treatment of Grade 3 Gliomas. Current treatment options in oncology, 2022, Volume: 23, Issue:9 Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Lymphoma, Follicular; Mutati	2022
Secondary cerebellopontine angle oligodendroglioma after cranial irradiation: a case report and literature review. The International journal of neuroscience, 2023, Volume: 133, Issue:4 Topics: Adult; Astrocytoma; Cerebellopontine Angle; Cranial Irradiation; Humans; Magnetic Resonance Imaging;	2023
Secondary cerebellopontine angle oligodendroglioma after cranial irradiation: a case report and literature review. The International journal of neuroscience, 2023, Volume: 133, Issue:4 Topics: Adult; Astrocytoma; Cerebellopontine Angle; Cranial Irradiation; Humans; Magnetic Resonance Imaging;	2023
Chemotherapy of High-Grade Astrocytomas in Adults. Progress in neurological surgery, 2018, Volume: 31 Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Grading; Te	2018
Chemotherapy of High-Grade Astrocytomas in Adults. Progress in neurological surgery, 2018, Volume: 31 Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Grading; Te	2018
Supratentorial low-grade diffuse astrocytoma: medical management. Seminars in oncology, 2014, Volume: 41, Issue:4 Topics: Antineoplastic Agents; Astrocytoma; Dacarbazine; Disease Progression; Humans; Neoplasm Grading; Nitr	2014
Supratentorial low-grade diffuse astrocytoma: medical management. Seminars in oncology, 2014, Volume: 41, Issue:4 Topics: Antineoplastic Agents; Astrocytoma; Dacarbazine; Disease Progression; Humans; Neoplasm Grading; Nitr	2014
Astrocytoma malignum in glioblastoma multiforme vertens with long term survival--case report and a literature review. Przeglad lekarski, 2014, Volume: 71, Issue:8 Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adjuvant;	2014
Astrocytoma malignum in glioblastoma multiforme vertens with long term survival--case report and a literature review. Przeglad lekarski, 2014, Volume: 71, Issue:8 Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adjuvant;	2014
Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. Molecules (Basel, Switzerland), 2009, Apr-16, Volume: 14, Issue:4 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbaz	2009
Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. Molecules (Basel, Switzerland), 2009, Apr-16, Volume: 14, Issue:4 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbaz	2009
[Prescription guidebook for temozolomide usage in brain tumors]. Bulletin du cancer, 2009, Volume: 96, Issue:5 Topics: Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Admi	2009
[Prescription guidebook for temozolomide usage in brain tumors]. Bulletin du cancer, 2009, Volume: 96, Issue:5 Topics: Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Admi	2009
High-grade glioma mouse models and their applicability for preclinical testing. Cancer treatment reviews, 2009, Volume: 35, Issue:8 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biomark	2009
High-grade glioma mouse models and their applicability for preclinical testing. Cancer treatment reviews, 2009, Volume: 35, Issue:8 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biomark	2009
Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas. International journal of radiation oncology, biology, physics, 2010, Oct-01, Volume: 78, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; H	2010
Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas. International journal of radiation oncology, biology, physics, 2010, Oct-01, Volume: 78, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; H	2010
Bevacizumab as a treatment option for radiation-induced cerebral necrosis. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2011, Volume: 187, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A	2011
Bevacizumab as a treatment option for radiation-induced cerebral necrosis. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2011, Volume: 187, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A	2011
Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro-oncology, 2003, Volume: 5, Issue:2 Topics: Animals; Astrocytoma; Clinical Trials as Topic; Dacarbazine; Humans; Oligodendroglioma; Temozolomide	2003
Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro-oncology, 2003, Volume: 5, Issue:2 Topics: Animals; Astrocytoma; Clinical Trials as Topic; Dacarbazine; Humans; Oligodendroglioma; Temozolomide	2003
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology, 2004, Aug-10, Volume: 63, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms	2004
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology, 2004, Aug-10, Volume: 63, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms	2004
Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2005, Volume: 21, Issue:6 Topics: Antineoplastic Agents, Alkylating; Arachnoid Cysts; Astrocytoma; Brain Neoplasms; Child; Child, Pres	2005
Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2005, Volume: 21, Issue:6 Topics: Antineoplastic Agents, Alkylating; Arachnoid Cysts; Astrocytoma; Brain Neoplasms; Child; Child, Pres	2005
Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. Journal of neuro-oncology, 2005, Volume: 71, Issue:3 Topics: Acute Disease; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosomes,	2005
Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. Journal of neuro-oncology, 2005, Volume: 71, Issue:3 Topics: Acute Disease; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosomes,	2005
[New place of the chemotherapy in gliomas]. Bulletin du cancer, 2005, Volume: 92, Issue:4 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Tr	2005
[New place of the chemotherapy in gliomas]. Bulletin du cancer, 2005, Volume: 92, Issue:4 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Tr	2005
[Chemotherapy for gliomas in children]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 9 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai	2005
[Chemotherapy for gliomas in children]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 9 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai	2005
Treatment of astrocytomas. Current opinion in neurology, 2005, Volume: 18, Issue:6 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Therapy; Humans;	2005
Treatment of astrocytomas. Current opinion in neurology, 2005, Volume: 18, Issue:6 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Therapy; Humans;	2005
Recent advances in the treatment of malignant astrocytoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Mar-10, Volume: 24, Issue:8 Topics: Antineoplastic Agents; Astrocytoma; Central Nervous System Neoplasms; Combined Modality Therapy; Dac	2006
Recent advances in the treatment of malignant astrocytoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Mar-10, Volume: 24, Issue:8 Topics: Antineoplastic Agents; Astrocytoma; Central Nervous System Neoplasms; Combined Modality Therapy; Dac	2006
The role of chemotherapy in the treatment of malignant astrocytomas. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2006, Volume: 33, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto	2006
The role of chemotherapy in the treatment of malignant astrocytomas. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2006, Volume: 33, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto	2006
Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? Critical reviews in oncology/hematology, 2006, Volume: 60, Issue:2 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carcinoma; Chemotherapy, Adjuvant;	2006
Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? Critical reviews in oncology/hematology, 2006, Volume: 60, Issue:2 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carcinoma; Chemotherapy, Adjuvant;	2006
[Glioma therapy up-date]. Neurologia (Barcelona, Spain), 2007, Volume: 22, Issue:3 Topics: Anticoagulants; Anticonvulsants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe	2007
[Glioma therapy up-date]. Neurologia (Barcelona, Spain), 2007, Volume: 22, Issue:3 Topics: Anticoagulants; Anticonvulsants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe	2007
Anaplastic astrocytoma in adults. Critical reviews in oncology/hematology, 2007, Volume: 63, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical T	2007
Anaplastic astrocytoma in adults. Critical reviews in oncology/hematology, 2007, Volume: 63, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical T	2007
Diagnosis and treatment of high-grade astrocytoma. Neurologic clinics, 2007, Volume: 25, Issue:4 Topics: Antineoplastic Agents; Astrocytoma; Brachytherapy; Brain Neoplasms; Dacarbazine; Diagnosis, Differen	2007
Diagnosis and treatment of high-grade astrocytoma. Neurologic clinics, 2007, Volume: 25, Issue:4 Topics: Antineoplastic Agents; Astrocytoma; Brachytherapy; Brain Neoplasms; Dacarbazine; Diagnosis, Differen	2007
[Recent advances in chemotherapy for malignant gliomas]. No shinkei geka. Neurological surgery, 2008, Volume: 36, Issue:2 Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Meta-A	2008
[Recent advances in chemotherapy for malignant gliomas]. No shinkei geka. Neurological surgery, 2008, Volume: 36, Issue:2 Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Meta-A	2008
Temozolomide in malignant gliomas. Seminars in oncology, 2000, Volume: 27, Issue:3 Suppl 6 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazi	2000
Temozolomide in malignant gliomas. Seminars in oncology, 2000, Volume: 27, Issue:3 Suppl 6 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazi	2000
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Seminars in oncology, 2000, Volume: 27, Issue:3 Suppl 6 Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic;	2000
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Seminars in oncology, 2000, Volume: 27, Issue:3 Suppl 6 Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic;	2000
Temozolomide and treatment of malignant glioma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:7 Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Gliobl	2000
Temozolomide and treatment of malignant glioma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:7 Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Gliobl	2000
Temozolomide for recurrent high-grade glioma. Seminars in oncology, 2001, Volume: 28, Issue:4 Suppl 13 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous System Neoplasms; Clinical Trials as	2001
Temozolomide for recurrent high-grade glioma. Seminars in oncology, 2001, Volume: 28, Issue:4 Suppl 13 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous System Neoplasms; Clinical Trials as	2001
A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. British journal of cancer, 2002, Feb-12, Volume: 86, Issue:4 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazi	2002
A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. British journal of cancer, 2002, Feb-12, Volume: 86, Issue:4 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazi	2002